Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes.

OBJECTIVE: A majority of adults with type 1 diabetes (T1D) are overweight (OW) or obese (OB) and often struggle to reach glycemic targets. Tirzepatide, a dual-incretin approved for type 2 diabetes (T2D) and OW/OB, has been shown to improve glucose control, reduce body weight, and insulin requirements in off-label adjunctive use for patients with T1D. This study evaluated changes in continuous glucose monitoring (CGM) data over 12-months of tirzepatide use in OW/OB adults with T1D. MATERIALS AND METHODS: This a single-center, retrospective, longitudinal case-control study included 61 OW/OB adults with T1D using tirzepatide and 54 computer-matched (for age, HbA1c, and weight) controls. CGM data were analyzed at baseline and every 3 months over a 15-month period (-3, 3, 6, 9, and 12 months). We assessed both within- and between-groups changes in CGM metrics from baseline at each time point. RESULTS: < 0.01). No severe hypoglycemia or diabetic ketoacidosis occurred in either group. CONCLUSIONS: We conclude that adjunctive tirzepatide treatment in OW/OB adults with T1D was associated with sustained improvements in CGM metrics over 12 months, without increased hypoglycemia risk in this real-world study. Proper long-term randomized control trials are needed to confirm our findings.